Peribulbar Block for Prevention of Oculocardiac Reflex

September 13, 2020 updated by: Mohammed yehia abdel latif, Fayoum University Hospital

Comparative Study Between Combined General Anesthesia With Peribulbar Block Versus Traditional General Anesthesia in Patients Undergoing Strabismus Surgery

Strabismus is a common ophthalmic problem in Egypt that usually requires surgical correction. This surgery primarily aims to improve alignment of visual axis but may be required only for cosmetic reasons. General anesthesia is mandatory for most cases however a concomitant local anesthetics administration is preferable to improve patient satisfaction, decrease postoperative analgesic requirements and reduce post-operative pain. Oculocardiac reflex is a noted serious complication that accompanies such surgeries and may be life threatening. Oculocardiac reflex (OCR) is one of the main challenges that face anesthesiologists during strabismus surgery. The incidence of OCR varies from 16 to 82 % in strabismus surgeries and this wide range does depend on the anesthetic agents, premedications, and the definition of OCR being used. Maintenance of adequate depth of anesthesia and the use of anti-cholinergic is the mainstay to reduce this risk. OCR is usually defined as a decrease in heart rate of more than 20 % from the baseline. This reflex is triggered by the pressure on the extra ocular muscles (EOM) or eyeball, orbital hematoma or trauma, the afferent limb is from orbital contents to ciliary ganglion then to the sensory nucleus of the trigeminal nerve near the fourth ventricle through the ophthalmic division of the trigeminal nerve. The main response of this reflex is transmitted through the vagus to the heart. This vagal stimulation leads to a decrease in heart rate (sinus bradycardia), contractility and arrhythmias such as atrioventricular block, ventricular fibrillation up to cardiac arrest.

The incidence of the OCR decreases with age and tends to be more pronounced in young healthy patients. It has been suggested that the anesthetic agents used during surgery influence the incidence of OCR. To date, the only successful method to interrupt an OCR is to stop the EOM traction, and then proceed with caution as surgery continues. Depth of anesthesia is another presumed factor having an impact on reducing of OCR incidence.

The response to surgical stimulus can be minimized or stopped with the help of peribulbar block.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The study will be performed from July 2019 to February 2020 at Fayoum University hospital after approval of the local institutional ethics committee and local institutional review board. The study design will be prospective, randomized, parallel groups, controlled clinical trial. A detailed informed consent will be signed by the eligible participants before recruitment and randomization.

Randomization & blinding:

It will be done by using computer-generated random numbers that will be placed in separate opaque envelopes that will be opened by study investigators just before the surgery. Neither the participants, the study investigators, the attending clinicians, nor the data collectors will be aware of groups' allocation till the study end. The Consolidated Standards of Reporting Trials (CONSORT) recommendations for reporting randomized, controlled clinical trials will be followed. This is the randomized case-control study. 30 patients will be randomly divided into 2 study groups .each group contains 15 patients; Group GA: Total 15 cases who will receive general anesthesia only, i.e., without peribulbar block.

Group GB: Total 15 cases who will receive general anesthesia with peribulbar block.

Anesthetic technique:

Preoperative preparations:

History taking, physical examination and investigation will be done according to local protocol designed to evaluate the patients which include complete blood count and coagulation profile. All cases will have a routine pre-operative check-up, starve for 6 h for solids and 2 hours for clear fluids and water. Written informed consent will be signed by adult patients or parents of pediatric participants.

Intraoperative technique and management:

Upon arrival to the operating room standard monitors (Pulse oximeter, Noninvasive blood pressure monitoring, and Electrocardiogram) will be applied and continued all over the operation and a peripheral intravenous (IV) cannula (20G) will be inserted.

After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.

Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.

Intraoperative OCR with decrease of heart rate more than 20% from baseline. If happened it will be managed by asking the operator to stop the surgical traction and giving 0.01 mg/kg of atropine. If cardiac arrest was identified, resuscitation will be according to advanced cardiac life support (ACLS) protocols.

Perioperative Nausea and vomiting will be treated by ondansetron 0.15 mg/kg intravenously over 15 min.

Postoperative monitoring, Pain control and follow up:

At the end of surgery, Participant will be transferred to postoperative anesthesia care unit (PACU) with standard monitoring applied. Pain will be evaluated by visual analog score (VAS) score from (0_ 100) (where; zero = no pain, 100=worst imaginable pain) assessed at 2 ,4, 6 ,12 ,24 and after 24 h.

Study Type

Interventional

Enrollment (Anticipated)

70

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Fayoum, Egypt, 1234
        • Recruiting
        • Faculty of Medicine -Fayoum University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 48 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients aged 10 years to 50 years
  • American society association (ASA) physical status I, II
  • Patient scheduled for a unilateral strabismus surgery.

Exclusion Criteria:

  • Refusal of local anesthesia.
  • Contraindications of local anesthesia e.g. allergy or hypersensitivity to local anesthetics or orbital inflammation .
  • Pregnancy
  • Glaucoma
  • Communication barrier between physician and patient e.g. impaired hearing, impaired mental status

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: the intervention group (G A)
Group general anaesthesia plus peribulbar block : Total 35 cases who will receive general anesthesia with peribulbar block (bupivacaine 0.5 % xylocaine 2% hyaluronidase with total volume 0.06 mg \kg (bupivacaine : (xylocaine :hyaluronidase ) 1:1) Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.

After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.

Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.

Other Names:
  • xylocaine hyaluronidase
Placebo Comparator: the control group (G B )

General group: Total 35 cases who will receive general anesthesia only, i.e., without peribulbar block. (Fentanyl 1µg\kg, atracurium 0.5 mg\kg and propofol 2mg \kg.

After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.

After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.

Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.

Other Names:
  • xylocaine hyaluronidase

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of Oculocardiac reflex .
Time Frame: 3 minutes after traction on extraocular muscles during squint surgery
Occurence of bradycardia with heart rate decrease by 20% from baseline value or if dysrhythmias or sinus arrest after traction on extraocular muscles
3 minutes after traction on extraocular muscles during squint surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Degree of post operative pain
Time Frame: 2 hours post operatively
Assessment by visual analog scale (VAS) score from 0 to 10 degree with 0 : no pain and 10: worst pain
2 hours post operatively
Degree of post operative pain
Time Frame: 4 hours postoperatively
Assessment by visual analog scale (VAS) score from 0 to 10 degree with 0 : no pain and 10: worst pain
4 hours postoperatively
Degree of post operative pain
Time Frame: 6 hours postoperatively
Assessment by visual analog scale (VAS) score from 0 to 10 degree with 0 : no pain and 10: worst pain
6 hours postoperatively
Degree of post operative pain
Time Frame: 12 hours postoperatively
Assessment by visual analog scale (VAS) score from 0 to 10 degree with 0 : no pain and 10: worst pain
12 hours postoperatively
Degree of post operative pain
Time Frame: 24 hours postoperatively
Assessment by visual analog scale (VAS) score from 0 to 10 degree with 0 : no pain and 10: worst pain
24 hours postoperatively
Incidence of postoperative nausea and vomiting (PONV)
Time Frame: 24 hours in the postoperative period

0: No nausea or vomiting

1: nausea or vomiting

24 hours in the postoperative period
Patient satisfaction
Time Frame: 2 hours postoperatively
According to satisfaction score from 0 to 3 (0:poor,1:fair, 2:good, 3:excellent)
2 hours postoperatively
Patient satisfaction
Time Frame: 4 hours postoperatively
According to satisfaction score from 0 to 3 (0:poor,1:fair, 2:good, 3:excellent)
4 hours postoperatively
Patient satisfaction
Time Frame: 6 hours postoperatively
According to satisfaction score from 0 to 3 (0:poor,1:fair, 2:good, 3:excellent)
6 hours postoperatively
Patient satisfaction
Time Frame: 12 hours postoperatively
According to satisfaction score from 0 to 3 (0:poor,1:fair, 2:good, 3:excellent)
12 hours postoperatively
Patient satisfaction
Time Frame: 24 hours postoperatively
According to satisfaction score from 0 to 3 (0:poor,1:fair, 2:good, 3:excellent)
24 hours postoperatively

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient's age
Time Frame: 1 hour before operation
In years
1 hour before operation
Patient's weight
Time Frame: 1 hour before operation
In kilograms
1 hour before operation
Patient's height
Time Frame: 1 hour before operation
In centimetres
1 hour before operation
Operation time
Time Frame: 5 minutes after end of surgery
In minutes
5 minutes after end of surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Maged Labib Boulos, MD, Faculty of Medicine -Fayoum University
  • Principal Investigator: Khalid Gamal Abu eleinen, MD, Cairo University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 14, 2019

Primary Completion (Anticipated)

September 14, 2020

Study Completion (Anticipated)

October 14, 2020

Study Registration Dates

First Submitted

September 4, 2020

First Submitted That Met QC Criteria

September 13, 2020

First Posted (Actual)

September 16, 2020

Study Record Updates

Last Update Posted (Actual)

September 16, 2020

Last Update Submitted That Met QC Criteria

September 13, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Strabismus

Clinical Trials on Bupivacaine

3
Subscribe